	US 11,981,740 B2
	BAFF-R antibodies and uses thereof
Hong Qin, Duarte, CA (US); Larry W. Kwak, Duarte, CA (US); Jingxing Li, Duarte, CA (US); and Kexin Huang, Duarte, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by CITY OF HOPE, Duarte, CA (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Aug. 16, 2021, as Appl. No. 17/403,698.
Application 17/403,698 is a continuation of application No. 16/307,434, granted, now 11,136,405, previously published as PCT/US2017/036181, filed on Jun. 6, 2017.
Claims priority of provisional application 62/346,324, filed on Jun. 6, 2016.
Prior Publication US 2022/0041743 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

20 Claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a B cell activating factor receptor (BAFF-R) antibody comprising a light chain variable region and a heavy chain variable region,

wherein said light chain variable region comprises:

a CDR L1 as set forth in SEQ ID NO:1, a CDR L2 as set forth in SEQ ID NO:2 and a CDR L3 as set forth in SEQ ID NO:3; and

wherein said heavy chain variable region comprises:

a CDR H1 as set forth in SEQ ID NO:4, a CDR H2 as set forth in SEQ ID NO:5, and a CDR H3 as set forth in SEQ ID NO:6.